That's what AstraZeneca ceo David Brennan says now that the House version of health care reform differs from the Senate version. How different? Well, the Senate version includes an $80 billion discount drugmakers agreed with the White House would be offered; the House version says that should be $140 billion. Brennan says the industry will fight if the House version survives.
"Right now the answer to that is yes," Brennan tells The Huffington Post. "We said there were principles we didn't want to see violated. And if those principles - price controls, Medicare rebates, moving dual eligibles back from Medicare and back into the Medicaid discount program - if those things happen, I can't see how we could be supportive of the program."
Brennan's remarks hold special significance since he is the chair this year of the industry trade group, PhRMA. Interestingly, he also pooh-poohed an IMS projection that the industry will gain up to $137 billion in revenue as the economy improves and, in particular, the deal with the White House and Senate.
"I talk to the IMS. They, I think, have gone from projecting the market would be flat to roughly two or three percent," he tells Huff. "I think you have to go back and look at their record of prospectively being able to project that out. And right now the market is softer than we probably expected it to be a few years ago."